All In Biotech

Investigational drug · Phase 2

TQB6411

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Lung Cancer, Esophageal Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "TQB6411"

First trial start

2026

Feb 12, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TQB6411", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Lung Cancer
  • Esophageal Cancer

Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "TQB6411" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Lung Cancer

  • FurmonertinibPhase 38 trials

    Allist Pharmaceuticals, Inc. · Non-Small Cell Lung Cancer, NSCLC, NSCLC Patients With Brain Metastasis

  • DB-1311BNT324Phase 34 trials

    BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors

  • AL2846Phase 33 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer

  • MHB039APhase 24 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer

  • MHB036CPhase 23 trials

    Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.